BACKGROUND: The transmission of electric fields using insulated electrodes has demonstrated that very low-intensity, properly tuned, intermediate-frequency electric fields, termed tumor-treating fields (TTFields), selectively stunts tumor cell growth and is accompanied by a decrease in tumor angiogenesis. PATIENTS AND METHODS: This open, prospective pilot study was designed to evaluate the safety, tolerability, and efficacy profile of TTFields treatment in patients with locally advanced and/or metastatic solid tumors using the NovoTTF100A(TM) device. All 6 patients were heavily pre-treated with several lines of therapy; no additional standard treatment option was available to them. TTFields treatment using continuous NovoTTF-100A lasted a minimum of 14 days and was very well tolerated. RESULTS: No related serious adverse events occurred. Outcomes showed 1 partial response of a treated skin metastasis from a primary breast cancer, 3 cases where tumor growth was arrested during treatment, and 1 case of disease progression. One mesothelioma patient experienced lesion regression near TTFields with simultaneous tumor stability or progression in distal areas. CONCLUSION: Although the number of patients in this study is small, the lack of therapy toxicity and the efficacy observed in data gathered to date indicate the potential of TTFields as a new treatment modality for solid tumors, definitely warranting further investigation. (c) 2008 S. Karger AG, Basel
BACKGROUND: The transmission of electric fields using insulated electrodes has demonstrated that very low-intensity, properly tuned, intermediate-frequency electric fields, termed tumor-treating fields (TTFields), selectively stunts tumor cell growth and is accompanied by a decrease in tumor angiogenesis. PATIENTS AND METHODS: This open, prospective pilot study was designed to evaluate the safety, tolerability, and efficacy profile of TTFields treatment in patients with locally advanced and/or metastatic solid tumors using the NovoTTF100A(TM) device. All 6 patients were heavily pre-treated with several lines of therapy; no additional standard treatment option was available to them. TTFields treatment using continuous NovoTTF-100A lasted a minimum of 14 days and was very well tolerated. RESULTS: No related serious adverse events occurred. Outcomes showed 1 partial response of a treated skin metastasis from a primary breast cancer, 3 cases where tumor growth was arrested during treatment, and 1 case of disease progression. One mesotheliomapatient experienced lesion regression near TTFields with simultaneous tumor stability or progression in distal areas. CONCLUSION: Although the number of patients in this study is small, the lack of therapy toxicity and the efficacy observed in data gathered to date indicate the potential of TTFields as a new treatment modality for solid tumors, definitely warranting further investigation. (c) 2008 S. Karger AG, Basel
Authors: Sandeep Mittal; Neil V Klinger; Sharon K Michelhaugh; Geoffrey R Barger; Susan C Pannullo; Csaba Juhász Journal: J Neurosurg Date: 2017-02-24 Impact factor: 5.115
Authors: Héctor Manuel Camué Ciria; Maraelys Morales González; Lisset Ortíz Zamora; Luis Enrique Bergues Cabrales; Gustavo Victoriano Sierra González; Luciana Oliveira de Oliveira; Rodrigo Zanella; Antonio Carlos Buzaid; Orlando Parise; Luciana Macedo Brito; Cesar Augusto Antunes Teixeira; Marina das Neves Gomes; Gleyce Moreno; Venicio Feo da Veiga; Marcos Telló; Carla Holandino Journal: Chin J Cancer Res Date: 2013-04 Impact factor: 5.087
Authors: Vânia Emerich Bucco de Campos; Cesar Augusto Antunes Teixeira; Venicio Feo da Veiga; Eduardo Ricci; Carla Holandino Journal: Int J Nanomedicine Date: 2010-11-15
Authors: J W Zimmerman; M J Pennison; I Brezovich; N Yi; C T Yang; R Ramaker; D Absher; R M Myers; N Kuster; F P Costa; A Barbault; B Pasche Journal: Br J Cancer Date: 2011-12-01 Impact factor: 7.640
Authors: Eilon D Kirson; Rosa S Schneiderman; Vladimír Dbalý; Frantisek Tovarys; Josef Vymazal; Aviran Itzhaki; Daniel Mordechovich; Zoya Gurvich; Esther Shmueli; Dorit Goldsher; Yoram Wasserman; Yoram Palti Journal: BMC Med Phys Date: 2009-01-08